Quantcast

Latest GlaxoSmithKline Stories

2014-10-23 23:04:35

ResolveHerpes is an All-Natural Mineral Detox Product that Helps to Remove Herpes from the Body Mandeville, LA (PRWEB) October 23, 2014 Resolve Herpes, a company that features an all-natural herpes treatment that can help to eliminate herpes symptoms from the body, is pleased to announce that they are now offering a special discount on orders for the popular ResolveHerpes product. For the next 48 hours, customers who place an order through the Resolve Herpes website and enter in the...

2014-10-23 08:34:40

DUBLIN, Oct. 23, 2014 /PRNewswire/ -- Research and Markets has announced the addition of the "Global Oral Hygiene Market 2014-2018" report to their offering. http://photos.prnewswire.com/prnvar/20130307/600769 There are many problems such as dental caries and tooth decay that affect the health of teeth. Treatment of such oral problems involves a high expenditure in case of further deterioration. The players in the Global Oral Hygiene market have been proactive in understanding the consumers...

2014-10-22 08:31:49

LONDON, October 22, 2014 /PRNewswire/ -- Amid continued pricing pressure in the Respiratory business, Sir Andrew Witty, CEO, has announced a restructuring of the pharmaceutical business. In a video interview he said: "What we've seen and we can identify are a number of opportunities to significantly reduce the cost structure of the organisation." Witty goes on to say that the company is considering a possible partial IPO of the ViiV business. Simon...

2014-10-16 08:30:25

EDISON, N.J., Oct. 16, 2014 /PRNewswire/ -- ContraVir Pharmaceuticals, Inc. (OTCBB: CTRV), a biopharmaceutical company focused on the development and commercialization of targeted antiviral therapies, announced today that it has entered into an agreement with Pharmaceutical Product Development, LLC (PPD), a leading contract research organization (CRO), to conduct a Phase 2b clinical trial of ContraVir's lead clinical asset, FV-100, in shingles patients. The planned Phase 2b study is...

2014-10-15 12:31:48

The COPD Market Will Fracture with the Continuing Entry of LABA/LAMAs and Other Later-to-Market Bronchodilators, According to Findings from Decision Resources Group BURLINGTON, Mass., Oct. 15, 2014 /PRNewswire/ -- Decision Resources Group finds that the emergence of the long-acting beta(2) agonist (LABA)/long-acting muscarinic antagonist (LAMA) drug class will help drive total sales across the chronic obstructive pulmonary disease (COPD) market in the United States, France, Germany, Italy,...

2014-10-15 08:29:07

Proceeds to Fund Phase 2b Study of FV-100 Fast-Acting Oral Antiviral EDISON, N.J., Oct. 15, 2014 /PRNewswire/ -- ContraVir Pharmaceuticals, Inc. (OTCBB: CTRV), a biopharmaceutical company focused on the development and commercialization of targeted antiviral therapies, announced today that it has closed a private placement of shares of Series A Convertible Preferred Stock to a non-U.S. investor with gross proceeds of $9.0 million. The Preferred Stock is convertible at any time into...

2014-10-10 12:24:40

RALEIGH, N.C., Oct. 10, 2014 /PRNewswire/ -- BioDelivery Sciences International, Inc. (BDSI) (NASDAQ: BDSI) announced that J. Chris Prue, RPh, MBA has joined BDSI as Vice President of Regulatory Affairs and Quality Assurance. Mr. Prue brings more than 30 years of pharmaceutical industry experience in regulatory affairs and quality assurance to BDSI. He has held positions of increasing responsibility at The Upjohn Company, Glaxo Inc., GlaxoWellcome and Purdue Pharma LP. Recently...

2014-10-09 08:27:08

CARLSBAD, Calif., Oct. 9, 2014 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced today that it has earned an $18 million milestone payment from GlaxoSmithKline (GSK) related to the advancement of the Phase 2/3 study of ISIS-TTR(Rx) in patients with familial amyloid polyneuropathy (FAP). http://photos.prnewswire.com/prnvar/20130807/LA60006LOGO "ISIS-TTR(Rx) is the most advanced drug in our collaboration with GSK, and aside from KYNAMRO, it is also the furthest...

2014-10-09 08:24:34

NEW YORK, Oct. 9, 2014 /PRNewswire/ -- A recently announced deal between GE Healthcare-subsidiary Clarient and Glaxo Smith Kline will create a force in cancer testing, according to Kalorama Information. The healthcare market research publisher tracks companion products, and says that the two entities will form a multi-purpose, data analytics- and companion diagnostics-driven network of laboratories. Kalorama Information recently released a market study, Companion Diagnostics Market, for...

2014-10-08 12:26:37

Emerging Anticytokines, Are Expected to Drive the Market Growth and Open a New Era of Personalized Medicine in Asthma, According to Findings from Decision Resources Group BURLINGTON, Mass., Oct. 8, 2014 /PRNewswire/ -- Decision Resources Group finds that the market for asthma will remain stable, increasing slightly from $15.1 billion in 2013 to $16.1 billion in 2023 in the United States, France, Germany, Italy, Spain, the United Kingdom, and Japan. As the current market leaders, which...


Word of the Day
ramage
  • Boughs or branches.
  • Warbling of birds in trees.
Related